These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 16944962)

  • 21. Pharmacogenetics and pharmacovigilance.
    Howland RH
    Drug Saf; 2009; 32(3):265-70. PubMed ID: 19338384
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacogenomics and adverse drug reactions: Primetime and not ready for primetime tests.
    Khan DA
    J Allergy Clin Immunol; 2016 Oct; 138(4):943-955. PubMed ID: 27720019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Promoting adverse drug reaction reporting: comparison of different approaches.
    Ribeiro-Vaz I; Santos CC; Cruz-Correia R
    Rev Saude Publica; 2016; 50():14. PubMed ID: 27143614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacovigiance: The spontaneous reporting system in Switzerland].
    Schäublin M
    Ther Umsch; 2015 Dec; 72(11-12):743-8. PubMed ID: 26654819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Therapeutic monitoring: analytic, pharmacokinetic and clinical aspects].
    Marquet P
    Acta Clin Belg; 1999; 53 Suppl 1():2-12. PubMed ID: 10216973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The contribution of pharmacogenetics to pharmacovigilance.
    Bondon-Guitton E; Despas F; Becquemont L
    Therapie; 2016 Apr; 71(2):223-8. PubMed ID: 27080842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Personalised pharmacogenetics. Evidence-based guidelines and clinical application of pharmacogenetic diagnostics].
    Stingl JC; Brockmöller J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Nov; 56(11):1509-21. PubMed ID: 24170080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics.
    Dahl ML; Sjöqvist F
    Ther Drug Monit; 2000 Feb; 22(1):114-7. PubMed ID: 10688272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre.
    Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F
    Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus.
    Mok CC
    Expert Rev Clin Immunol; 2017 Jan; 13(1):35-41. PubMed ID: 27417340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and clinical gains of nurse-led medication monitoring profiles.
    Gabe ME; Jordan SE
    J Nurs Manag; 2014 Apr; 22(3):331-49. PubMed ID: 23701013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fixed-dose combination products and unintended drug interactions: urgent need for pharmacogenetic evaluation.
    Duconge J; Ruaño G
    Pharmacogenomics; 2015; 16(15):1685-8. PubMed ID: 26431456
    [No Abstract]   [Full Text] [Related]  

  • 34. Incidence and costs of adverse drug reactions during hospitalisation: computerised monitoring versus stimulated spontaneous reporting.
    Dormann H; Muth-Selbach U; Krebs S; Criegee-Rieck M; Tegeder I; Schneider HT; Hahn EG; Levy M; Brune K; Geisslinger G
    Drug Saf; 2000 Feb; 22(2):161-8. PubMed ID: 10672897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Falls: the adverse drug reaction of the elderly and the impact of pharmacogenetics.
    Just KS; Schneider KL; Schurig M; Stingl JC; Brockmöller J
    Pharmacogenomics; 2017 Aug; 18(13):1281-1297. PubMed ID: 28776468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
    Chouchana L; Narjoz C; Beaune P; Loriot MA; Roblin X
    Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database.
    Szarfman A; Machado SG; O'Neill RT
    Drug Saf; 2002; 25(6):381-92. PubMed ID: 12071774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Filling quality of the reports of adverse drug reactions received at the Pharmacovigilance Centre of São Paulo (Brazil): missing information hinders the analysis of suspected associations.
    Ribeiro A; Lima S; Zampieri ME; Peinado M; Figueras A
    Expert Opin Drug Saf; 2017 Dec; 16(12):1329-1334. PubMed ID: 28817316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacoepidemiology and its input to pharmacovigilance.
    Faillie JL; Montastruc F; Montastruc JL; Pariente A
    Therapie; 2016 Apr; 71(2):211-6. PubMed ID: 27080840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacogenetics and prediction of side effects of drugs].
    Harrak M; Khabbal Y; Amarti A; El Hassouni M; Ouldim K
    Ann Biol Clin (Paris); 2014; 72(4):405-12. PubMed ID: 25119798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.